A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at Moderately High Risk and High Risk for CHD

Merck & Co., Inc.0 个研究点目标入组 1,293 人开始时间: 2007年8月28日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Merck & Co., Inc.
入组人数: 1,293

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Patient is a male or post menopausal female and =65 years of age on the day of signing informed consent.
•Patient meets one of the following criteria:
•oTherapy naïve patients who are at high risk for CHD with established coronary and other atherosclerotic vascular disease or,
•Note: Established atherosclerotic vascular disease includes history of myocardial infarction, stable angina, coronary artery procedures (angioplasty or bypass surgery) or evidence of clinically significant myocardial ischemia. Other atherosclerotic vascular disease includes clinical manifestations of noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease [transient ischemic attacks or stroke of carotid origin or >50% obstruction of a carotid artery]).
•Therapy naïve is defined as not being treated with a lipid lowering agent within 6 weeks (8 weeks if a fibrate) prior to Visit 2 (Week -1).
•oTherapy naïve patients who are at high risk for CHD without atherosclerotic vascular disease who have diabetes or,
•oTherapy naïve patients who are at high risk for CHD without atherosclerotic vascular disease or diabetes with =2 risk factors and a 10-year risk for CHD >20% (as determined by the Framingham calculation) or,
•oTherapy naïve patients, or patients rendered naïve by the appropriate prior washout, who are at moderately high risk for CHD with =2 risk factors and a 10-year risk for CHD 10-20% (as determined by the Framingham calculation).
•Note: Patients rendered naïve is defined as washed out of a lipid lowering agent for 6 weeks (8 weeks if a fibrate) prior to Visit 2 (Week -1).
•Patient has a baseline LDL-C level of =130 mg/dL at Visit 2 (Week -1).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Patient has a hypersensitivity or intolerance to ezetimibe, simvastatin or atorvastatin or any component of these medications.
•Patient has exclusionary laboratory values at Visit 1 (Week -3) for either test listed in the table below:
•Laboratory TestExclusionary Value
•liver transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST])> 1.5 X ULN with no active liver disease
•Creatine kinase (CK)> 2 X ULN
•Patient’s triglycerides (TG) are > 350 mg/dL (3.96 mmol/L) at Visit 2.
•Patient has uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins (i.e., secondary causes of hyperlipidemia, such as hypothyroidism or hyperthyroidism).
•Note: A patient with hyper or hypothyroidism is defined by a TSH below the central laboratory's lower limit of the normal reference range or > 20% above the upper limit of the normal reference range. For patients receiving thyroid hormone, there is no lower TSH threshold for entry and the patient must be on a stable dose for > or equal to 6 weeks before the randomization visit. For patients whose TSH is above the entry criteria, thyroid hormone therapy may be adjusted or initiated provided there is time to stabilize the patient and still meet the enrollment timelines. One redraw will be allowed if the original TSH value is less than 40% above or below the reference range, but the patient must meet the criterion upon redraw.
•Patient has congestive heart failure defined by NYHA (New York Heart Association) Class III or IV.
•Patient has unstable angina pectoris.
•Patient has had a myocardial infarction, coronary artery bypass surgery, angioplasty or uncontrolled or severe peripheral artery disease within 3 months of Visit 1 (Week -3).
•Patient has had a partial ileal bypass, gastric bypass, or other significant intestinal malabsorption.
•Patient has uncontrolled hypertension (treated or untreated) with systolic blood pressure >160 mm Hg or diastolic >100 mm Hg at Visit 1 (Week -3). Investigators are encouraged to maximize blood pressure control according to current guidelines prior to randomization.
•Patient has impaired renal function (creatinine =2.0 mg/d [176.8 mmol/L]) or a history of nephrotic range proteinuria at Visit 1 (Week -3).
•Patient has uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins (i.e., secondary causes of hyperlipidemia), such as Cushing syndrome at Visit 1 (Week -3).
•Patient has type 2 diabetes mellitus that is poorly controlled (HbA1c =8.5% at Visit 1 (Week -3) or newly diagnosed (within 3 months of Visit 1) and/or patient has recent history of repeated hypoglycemia or unstable glycemic control.
•Patient has disorders of the hematologic, digestive, or central nervous systems including cerebrovascular disease and degenerative disease that would limit study evaluation or participation.
•Patient is known to be HIV positive.
•Patient has a history of malignancy = 5 years prior to signing informed consent, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer.
•Patient is currently taking cyclosporine, erythromycin, azole antifungals (i.e., itraconazole, ketoconazole, fluconazole) or fusidic acid.

研究者

发起方

Merck & Co., Inc.

相似试验

进行中（未招募）

不适用

A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder

EUCTR2010-019925-33-CZAstraZeneca AB940

进行中（未招募）

1 期

A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. - Extended Release Niacin/Laropiprant – Lipids

EUCTR2007-002017-39-FRaboratoires Merck Sharp & Dohme - Chibret1,250

进行中（未招募）

1 期

A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder

EUCTR2010-019925-33-LVAstraZeneca AB940

进行中（未招募）

1 期

EUCTR2007-002017-39-DKMerck & Co., Inc.1,250

进行中（未招募）

不适用

A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of RWJ-800088 on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thrombocytopenia in Subjects with Non-Small Cell Lung Cancer Receiving Gemcitabine and Either Carboplatin or Cisplatin - n/a

EUCTR2007-007520-17-BEJanssen-Cilag International N.V, Turnhoutseweg 30, 2340 Beerse, Belgium148